

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11829273/publications.pdf>

Version: 2024-02-01

182
papers

13,790
citations

22132

59
h-index

22147

113
g-index

184
all docs

184
docs citations

184
times ranked

10373
citing authors

#	ARTICLE	IF	CITATIONS
1	Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 825-835.	1.8	5
2	Functional hypothalamic amenorrhoea: a diagnosis of exclusion. <i>Medical Journal of Australia</i> , 2022, 216, 73-76.	0.8	2
3	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. <i>The Lancet Healthy Longevity</i> , 2022, 3, e109-e118.	2.0	15
4	Treating menopause " MHT and beyond. <i>Nature Reviews Endocrinology</i> , 2022, 18, 490-502.	4.3	37
5	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Sexual Medicine</i> , 2021, 18, 849-867.	0.3	40
6	Longitudinal changes over three years in sex steroid hormone levels in women aged 70 years and over. <i>Clinical Endocrinology</i> , 2021, 94, 443-448.	1.2	10
7	Use of Testosterone in Postmenopausal Women. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 113-124.	1.2	1
8	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Trial. <i>BMJ</i> , 2021, 373, n1111.	0.8	21
9	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Climacteric</i> , 2021, 24, 533-550.	1.1	4
10	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Women's Health</i> , 2021, 30, 474-491.	1.5	22
11	Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. <i>Human Reproduction</i> , 2021, 36, 1611-1620.	0.4	10
12	Testosterone and androstenedione are positively associated with anti-Müllerian hormone in premenopausal women. <i>Clinical Endocrinology</i> , 2021, 95, 752-759.	1.2	1
13	Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. <i>Human Reproduction</i> , 2021, 37, 109-118.	0.4	11
14	Associations between androgens and sexual function in premenopausal women: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 693-702.	5.5	30
15	Prevalence of Low Sexual Desire with Associated Distress Across the Adult Life Span: An Australian Cross-Sectional Study. <i>Journal of Sexual Medicine</i> , 2020, 17, 1885-1895.	0.3	10
16	Approach to Managing a Postmenopausal Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3792-3806.	1.8	3
17	Response to Letter to the Editor: "Distribution of Body Hair in Young Australian Women and Associations with Serum Androgen Concentrations". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3049-e3050.	1.8	0
18	Response to Letter to the Editor: "Global Consensus Position Statement on the Use of Testosterone Therapy for Women". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2313-e2314.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Estrone Is a Strong Predictor of Circulating Estradiol in Women Age 70 Years and Older. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3348-e3354.	1.8	14
20	Androgen Therapy for Postmenopausal Women. , 2020, , 187-193.		0
21	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1186-1195.	1.8	10
22	The prevalence of sexual dysfunctions and sexually related distress in young women: a cross-sectional survey. <i>Fertility and Sterility</i> , 2020, 113, 426-434.	0.5	22
23	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2299-e2307.	1.8	20
24	Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Sexual Medicine</i> , 2020, 17, 585-594.	0.3	5
25	The prevalence of hypoactive sexual desire disorder in Australian and Iranian women at midlife. <i>Menopause</i> , 2020, 27, 1274-1280.	0.8	3
26	Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 754-766.	5.5	140
27	Androgens During the Reproductive Years: What Is Normal for Women?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5382-5392.	1.8	76
28	Effects of testosterone therapy for women: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , 2019, 8, 19.	2.5	15
29	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4660-4666.	1.8	147
30	Global Consensus Position Statement on the use of Testosterone Therapy for Women. <i>Maturitas</i> , 2019, 128, 89-93.	1.0	12
31	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Sexual Medicine</i> , 2019, 16, 1331-1337.	0.3	22
32	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Climacteric</i> , 2019, 22, 429-434.	1.1	50
33	Challenges in recruitment to an epidemiological study of young Australian women: the Grolloâ€Ruzzene Foundation Young Womenâ€™s Health Study. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 131-136.	0.8	16
34	Exogenous Testosterone Does Not Influence 11-Oxygenated C19 Steroid Concentrations in Healthy Postmenopausal Women. <i>Journal of the Endocrine Society</i> , 2019, 3, 670-677.	0.1	10
35	Testosterone and Estrone Increase From the Age of 70 Years: Findings From the Sex Hormones in Older Women Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6291-6300.	1.8	37
36	Depressive symptoms and associated factors among Iranian women at midlife: a community-based, cross-sectional study. <i>Menopause</i> , 2019, 26, 1125-1132.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Prevalence of sexual symptoms in relation to menopause in women in Asia: a systematic review. <i>Menopause</i> , 2018, 25, 231-238.	0.8	12
38	The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. <i>Mayo Clinic Proceedings</i> , 2018, 93, 467-487.	1.4	166
39	Identification of the Gender-Specific Health Needs of Women Following Lung Transplantation. <i>Journal of Women's Health</i> , 2018, 27, 485-491.	1.5	1
40	Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. <i>Menopause</i> , 2018, 25, 1331-1338.	0.8	14
41	Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4146-4154.	1.8	42
42	Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2018, 24, 694-709.	5.2	134
43	Androgens in postmenopausal women. <i>Gynäkologische Endokrinologie</i> , 2018, 16, 123-127.	0.1	0
44	The benefits of adding metformin to tamoxifen to protect the endometrium—A randomized placebo-controlled trial. <i>Clinical Endocrinology</i> , 2018, 89, 605-612.	1.2	20
45	Types of urinary incontinence in Bangladeshi women at midlife: Prevalence and risk factors. <i>Maturitas</i> , 2018, 116, 18-23.	1.0	13
46	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. <i>Menopause</i> , 2018, 25, 837-847.	0.8	105
47	Moderate—Severe Vasomotor Symptoms Are Associated with Moderate—Severe Depressive Symptoms. <i>Journal of Women's Health</i> , 2017, 26, 712-718.	1.5	46
48	Hypoactive sexual desire dysfunction in community-dwelling older women. <i>Menopause</i> , 2017, 24, 391-399.	0.8	32
49	Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. <i>Journal of Sexual Medicine</i> , 2017, 14, 675-686.	0.3	72
50	Androgens in postmenopausal women: a review. <i>Menopause</i> , 2017, 24, 970-979.	0.8	33
51	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3647-3661.	1.8	89
52	Aromatase Inhibitors Are Associated with Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study. <i>Journal of Sexual Medicine</i> , 2017, 14, 1566-1574.	0.3	23
53	Vasomotor symptoms are associated with depressive symptoms in community-dwelling older women. <i>Menopause</i> , 2017, 24, 1365-1371.	0.8	3
54	Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. <i>Menopause</i> , 2017, 24, 1313-1322.	0.8	24

#	ARTICLE	IF	CITATIONS
55	Low use of effective and safe therapies for moderate to severe menopausal symptoms. <i>Menopause</i> , 2016, 23, 11-17.	0.8	30
56	Symptomatic pelvic floor disorders in community-dwelling older Australian women. <i>Maturitas</i> , 2016, 85, 34-41.	1.0	41
57	Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women. <i>Maturitas</i> , 2016, 94, 84-86.	1.0	5
58	Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction. <i>Journal of Sexual Medicine</i> , 2016, 13, 305-316.	0.3	75
59	Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey. <i>Menopause</i> , 2016, 23, 731-739.	0.8	22
60	Menopausal vasomotor symptoms are associated with poor self-assessed work ability. <i>Maturitas</i> , 2016, 87, 33-39.	1.0	49
61	Androgens and Female Sexual Function and Dysfunction—Findings From the Fourth International Consultation of Sexual Medicine. <i>Journal of Sexual Medicine</i> , 2016, 13, 168-178.	0.3	85
62	Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. <i>Fertility and Sterility</i> , 2016, 105, 149-155.e1.	0.5	41
63	Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. <i>Menopause</i> , 2015, 22, 694-701.	0.8	90
64	Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40–65 years. <i>Medical Journal of Australia</i> , 2015, 203, 146-146.	0.8	16
65	Menopausal hormone therapy—ovarian cancer risk revisited. <i>Nature Reviews Endocrinology</i> , 2015, 11, 322-323.	4.3	3
66	Testosterone in women: can the challenges be met?. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 588-590.	5.5	6
67	Menopause. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15004.	18.1	288
68	Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. <i>Menopause</i> , 2015, 22, 44-49.	0.8	20
69	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3975-4011.	1.8	589
70	Testosterone in women—the clinical significance. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 980-992.	5.5	181
71	Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. <i>Maturitas</i> , 2015, 81, 487-492.	1.0	49
72	Bangladesh Midlife Women's Health Study (BMWHS): Methods, challenges and experiences. <i>Maturitas</i> , 2015, 80, 89-94.	1.0	10

#	ARTICLE	IF	CITATIONS
73	Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. <i>Clinical Endocrinology</i> , 2014, 81, 621-628.	1.2	26
74	Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. <i>Menopause</i> , 2014, 21, 1075-1081.	0.8	48
75	Testosterone Improves Antidepressant-Emergent Loss of Libido in Women: Findings from a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Sexual Medicine</i> , 2014, 11, 831-839.	0.3	36
76	Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women. <i>Menopause</i> , 2014, 21, 410-414.	0.8	22
77	Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. <i>Maturitas</i> , 2014, 79, 279-286.	1.0	36
78	Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3489-3510.	1.8	261
79	A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. <i>Psychoneuroendocrinology</i> , 2014, 43, 52-61.	1.3	26
80	The association between vasomotor symptoms and depression during perimenopause: A systematic review. <i>Maturitas</i> , 2014, 77, 111-117.	1.0	75
81	Androgen treatment of postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 142, 107-114.	1.2	31
82	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013, 381, 805-816.	6.3	1,664
83	Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2013, 10, 3069-3079.	0.3	53
84	Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women. <i>Menopause</i> , 2013, 20, 1020-1026.	0.8	17
85	Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women. <i>Menopause</i> , 2013, 20, 640-645.	0.8	18
86	Androgen use for low sexual desire in midlife women. <i>Menopause</i> , 2013, 20, 795-797.	0.8	5
87	Urinary Incontinence in Young Nulligravid Women. <i>Annals of Internal Medicine</i> , 2012, 157, 87.	2.0	40
88	Sexual Function, Incontinence, and Wellbeing in Women after Rectal Cancer—A Review of the Evidence. <i>Journal of Sexual Medicine</i> , 2012, 9, 2749-2758.	0.3	46
89	The contribution of SHBG to the variation in HOMA-IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women. <i>Clinical Endocrinology</i> , 2012, 77, 541-547.	1.2	28
90	Hormonal therapies for new onset and relapsed depression during perimenopause. <i>Maturitas</i> , 2012, 73, 127-133.	1.0	37

#	ARTICLE	IF	CITATIONS
91	An update on the pharmacological management of female sexual dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2131-2142.	0.9	23
92	Efficacy and Safety of Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women. <i>Journal of Sexual Medicine</i> , 2012, 9, 1134-1148.	0.3	91
93	Incidence and Resolution Rates of Different Types of Urinary Incontinence in Women: Findings From a Cohort Study. <i>Journal of Urology</i> , 2011, 185, 1331-1337.	0.2	27
94	Vaginal DHEA to treat menopause related atrophy: A review of the evidence. <i>Maturitas</i> , 2011, 70, 22-25.	1.0	56
95	Testosterone improves verbal learning and memory in postmenopausal women: Results from a pilot study. <i>Maturitas</i> , 2011, 70, 307-311.	1.0	42
96	Androgenic hormones and aging – The link with female sexual function. <i>Hormones and Behavior</i> , 2011, 59, 745-753.	1.0	37
97	Cardiovascular and cancer safety of testosterone in women. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 198-203.	1.2	39
98	Prevalence of fecal incontinence and its relationship with urinary incontinence in women living in the community. <i>Menopause</i> , 2011, 18, 685-689.	0.8	43
99	Sexual Function After Breast Cancer. <i>Journal of Sexual Medicine</i> , 2011, 8, 294-302.	0.3	150
100	DHEA Replacement for Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1642-1653.	1.8	131
101	Urinary incontinence is associated with lower psychological general well-being in community-dwelling women. <i>Menopause</i> , 2010, 17, 332-337.	0.8	37
102	Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: An fMRI study. <i>Neuropsychologia</i> , 2010, 48, 529-535.	0.7	93
103	Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. <i>Psychoneuroendocrinology</i> , 2010, 35, 1142-1147.	1.3	106
104	Endocrine Aspects of Women’s Sexual Function. <i>Journal of Sexual Medicine</i> , 2010, 7, 561-585.	0.3	85
105	Should women receive androgen replacement therapy, and if so, how?. <i>Clinical Endocrinology</i> , 2010, 72, 149-154.	1.2	8
106	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, s1-s66.	1.8	512
107	Drugs for the treatment of menopausal symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1329-1341.	0.9	7
108	DHEA for postmenopausal women: A review of the evidence. <i>Maturitas</i> , 2010, 66, 172-179.	1.0	79

#	ARTICLE	IF	CITATIONS
109	Validity and cultural equivalence of the standard Greene Climacteric Scale in Hong Kong. <i>Menopause</i> , 2010, 17, 630-635.	0.8	20
110	Testosterone for low libido in postmenopausal women not using systemic oestrogen therapy. <i>Medical Journal of Australia</i> , 2009, 191, 134-135.	0.8	2
111	Lack of Knowledge of Hormone Receptor Status and Use of Endocrine Therapy in Invasive Breast Cancer. <i>Journal of Women's Health</i> , 2009, 18, 1975-1980.	1.5	12
112	The Effect of Transdermal Testosterone on Mammographic Density in Postmenopausal Women Not Receiving Systemic Estrogen Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4907-4913.	1.8	36
113	The Incidence of Invasive Breast Cancer Among Women Prescribed Testosterone for Low Libido. <i>Journal of Sexual Medicine</i> , 2009, 6, 1850-1856.	0.3	38
114	A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido. <i>Journal of Sexual Medicine</i> , 2009, 6, 2579-2590.	0.3	44
115	Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. <i>Maturitas</i> , 2009, 62, 134-139.	1.0	78
116	The safety of 52 weeks of oral DHEA therapy for postmenopausal women. <i>Maturitas</i> , 2009, 63, 240-245.	1.0	49
117	Low back pain and disability in community-based women. <i>Menopause</i> , 2009, 16, 24-29.	0.8	17
118	Understanding female sexual function. <i>Menopause</i> , 2009, 16, 425-426.	0.8	9
119	Prevalence and incidence of urinary incontinence in women: Review of the literature and investigation of methodological issues. <i>International Journal of Urology</i> , 2008, 15, 230-234.	0.5	124
120	Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer. <i>BMC Cancer</i> , 2008, 8, 126.	1.1	33
121	FSD PHARMACOTHERAPY: Tibolone and Transdermal E2/NETA for the Treatment of Female Sexual Dysfunction in Naturally Menopausal Women: Results of a Randomized Active-Controlled Trial. <i>Journal of Sexual Medicine</i> , 2008, 5, 646-656.	0.3	102
122	Sexual Function in Well Women: Stratification by Sexual Satisfaction, Hormone Use, and Menopause Status. <i>Journal of Sexual Medicine</i> , 2008, 5, 1214-1222.	0.3	68
123	Pharmacological Therapy for Female Sexual Dysfunction. <i>Drugs</i> , 2008, 68, 259-264.	4.9	15
124	Androgen Replacement Therapy in Androgen-Deficient Women with Hypopituitarism. <i>Drugs</i> , 2008, 68, 2085-2093.	4.9	6
125	High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life. <i>Arthritis Research and Therapy</i> , 2008, 10, R27.	1.6	21
126	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. <i>New England Journal of Medicine</i> , 2008, 359, 2005-2017.	13.9	427

#	ARTICLE	IF	CITATIONS
127	Methodology and Challenges to Recruitment to a Randomized, Double-Blind, Placebo-Controlled Trial of Oral DHEA in Postmenopausal Women. <i>Journal of Women's Health</i> , 2008, 17, 1559-1565.	1.5	8
128	Dehydroepiandrosterone Sulfate Levels Are Associated with More Favorable Cognitive Function in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 801-808.	1.8	95
129	Sexual health consequences of premature ovarian failure. <i>Menopause</i> , 2008, 15, 5-6.	0.8	3
130	A pragmatic approach to the classification of menopausal status for community-based research. <i>Menopause</i> , 2008, 15, 978-983.	0.8	35
131	DHEA therapy for women: effect on sexual function and wellbeing. <i>Human Reproduction Update</i> , 2007, 13, 239-248.	5.2	86
132	Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. <i>Menopause</i> , 2007, 14, 630-638.	0.8	62
133	Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease ? a community-based study. <i>Clinical Endocrinology</i> , 2007, 66, 070210034307001-???.	1.2	73
134	Androgen therapy in women: What we think we know. <i>Experimental Gerontology</i> , 2007, 42, 457-462.	1.2	16
135	Intervention: Androgens. , 2007, , 799-812.		0
136	Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3697-3710.	1.8	286
137	Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women. <i>Menopause</i> , 2006, 13, 770-779.	0.8	146
138	Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. <i>Menopause</i> , 2006, 13, 387-396.	0.8	230
139	Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. <i>Menopause</i> , 2006, 13, 600-608.	0.8	41
140	Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. <i>Menopause</i> , 2006, 13, 37-45.	0.8	76
141	Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. <i>Menopause</i> , 2006, 13, 65-71.	0.8	53
142	A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. <i>Psychoneuroendocrinology</i> , 2006, 31, 543-547.	1.3	106
143	The use of androgens for female sexual dysfunction. <i>Nature Reviews Urology</i> , 2006, 3, 176-177.	1.4	4
144	Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. <i>Menopause</i> , 2005, 12, 210-215.	0.8	66

#	ARTICLE	IF	CITATIONS
145	Circulating Androgen Levels and Self-reported Sexual Function in Women. JAMA - Journal of the American Medical Association, 2005, 294, 91.	3.8	451
146	Treatment of menopausal symptoms: what shall we do now?. Lancet, The, 2005, 366, 409-421.	6.3	116
147	Measurement of total testosterone in women: comparison of a direct radioimmunoassay versus radioimmunoassay after organic solvent extraction and celite column partition chromatography. Fertility and Sterility, 2005, 84, 1698-1704.	0.5	26
148	Testosterone for peri and postmenopausal women. The Cochrane Library, 2005, , CD004509.	1.5	104
149	Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women. Endocrine Reviews, 2004, 25, 374-388.	8.9	196
150	The use of testosterone after menopause. The Journal of the British Menopause Society, 2004, 10, 65-69.	1.3	5
151	Endocrine Aspects of Female Sexual Dysfunction. Journal of Sexual Medicine, 2004, 1, 82-86.	0.3	98
152	Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings. Seminars in Arthritis and Rheumatism, 2004, 34, 631-636.	1.6	49
153	Postmenopausal testosterone therapy and breast cancer risk. Maturitas, 2004, 49, 267-275.	1.0	37
154	Hormone replacement therapy: current controversies. Clinical Endocrinology, 2003, 58, 249-261.	1.2	79
155	The role of androgen therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 165-175.	2.2	18
156	Androgens in women. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 363-366.	1.2	136
157	What is the Rationale for Androgen Therapy for Women?. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 77-84.	1.8	19
158	Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause, 2003, 10, 390-398.	0.8	246
159	New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2470-2478.	1.8	112
160	Menopause: new therapies. Medical Journal of Australia, 2003, 178, 634-637.	0.8	8
161	Rationale for Treating Hypoandrogenism in Women. , 2003, , 365-379.		2
162	The effects of tibolone on mood and libido. Menopause, 2002, 9, 162-170.	0.8	81

#	ARTICLE	IF	CITATIONS
163	When to suspect androgen deficiency other than at menopause1 1Reprints will not be available.. Fertility and Sterility, 2002, 77, 68-71.	0.5	66
164	The role of androgen therapy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 383-393.	1.4	9
165	Testosterone insufficiency in women: fact or fiction?. World Journal of Urology, 2002, 20, 106-110.	1.2	41
166	Androgen Deficiency and Abnormality in Women. , 2002, , 477-488.		0
167	Testosterone influences libido and well being in women. Trends in Endocrinology and Metabolism, 2001, 12, 33-37.	3.1	157
168	Minireview: Aromatase and the Regulation of Estrogen Biosynthesisâ€™Some New Perspectives. Endocrinology, 2001, 142, 4589-4594.	1.4	405
169	Evidence That Parenteral Testosterone Therapy May Improve Endothelium-Dependent and -Independent Vasodilation in Postmenopausal Women Already Receiving Estrogen. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 158-161.	1.8	153
170	Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause, 2000, 7, 395-401.	0.8	145
171	Androgens. , 2000, , 445-458.		1
172	Androgen treatment in women. Medical Journal of Australia, 1999, 170, 545-549.	0.8	29
173	Androgen Replacement in Women. , 1999, , 401-417.		1
174	The rationale for physiological testosterone replacement in women. Bailliere's Clinical Endocrinology and Metabolism, 1998, 12, 391-405.	1.0	22
175	PREMATURE OVARIAN FAILURE. Endocrinology and Metabolism Clinics of North America, 1998, 27, 989-1006.	1.2	164
176	Phytoestrogens¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 297-303.	1.8	273
177	The clinical use of androgens in female sexual disorders. Journal of Sex and Marital Therapy, 1998, 24, 153-163.	1.0	41
178	Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. New England Journal of Medicine, 1997, 337, 595-601.	13.9	189
179	Premature ovarian failure. Maturitas, 1996, 23, 1-8.	1.0	43
180	Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas, 1995, 21, 227-236.	1.0	488

#	ARTICLE	IF	CITATIONS
181	Testosterone use in women. , 0, , 494-516.		1
182	Androgen therapy for postmenopausal women. , 0, , 136-141.		0